GUD and CPH?Debt-free profitable Cipher Pharmaceuticals (CPH) is dirt-cheap trading just 1.3 times its EBITDA. Some emotional short-sighted investors dumped it last week because of the news regarding BHC, although the news regarding Trulance have no impact on CPH's revenue.
Insiders own 41% in CPH, so their interests are aligned with shareholders'.
I wish GUD acquired a stake in dirt-cheap CPH asap given also that CPH has a handful of promising drugs with significant upside potential in the pipeline.